Laboratory of Sleep and Heart, Pronto Socorro Cardiológico de Pernambuco - University of Pernambuco.
Postgraduate Degree in Health Sciences, University of Pernambuco, Recife, PE.
Blood Press Monit. 2021 Jun 1;26(3):224-229. doi: 10.1097/MBP.0000000000000517.
Patients with masked hypertension have a higher incidence of target organ damage, including increased left ventricular mass and carotid atherosclerosis and cardiovascular events when compared with normotensive patients. The adverse cardiovascular risks are even greater in patients already taking antihypertensive medication.
To identify the prevalence and clinical characteristics of masked hypertension in a large multicenter Brazilian sample that underwent office and home blood pressure monitoring.
This was an observational cross-sectional analytical study based on secondary data from the teleMRPA online platform, which included 32 cities from 15 states in the five regions of Brazil. The database included 3704 outpatient participants with office blood pressure <140/90 mmHg who performed home blood pressure monitoring for diagnostic investigation (diagnosis group; n = 1819) or treatment (treatment group; n = 1885) of hypertension in 2018.
The prevalence of masked hypertension was 18.0% in the whole studied population and 15.4% and 20.4% in the diagnostic and treatment group, respectively. Masked hypertension was more frequently detected in patients with office blood pressure classified as high normal [systolic blood pressure (SBP) = 130-139 mmHg or diastolic blood pressure (DBP) = 85-89 mmHg], followed by those classified as normal (SBP = 120-129 mmHg or DBP = 80-84 mmHg) and optimal (SBP < 120 mmHg and DBP < 80 mmHg), with respective prevalence of 28.3, 13.4 and 4.4% in the diagnostic group and 30.8, 18.8 and 7.1% in the treatment group.
Masked hypertension has a significant prevalence among individuals with office blood pressure <140/90 mmHg, which is greater with patients with high normal office blood pressure and even higher in patients already using antihypertensive medication.
与正常血压患者相比，隐匿性高血压患者的靶器官损害发生率更高，包括左心室质量增加、颈动脉粥样硬化和心血管事件。在已经服用降压药物的患者中，心血管不良风险甚至更大。
在一个接受诊室和家庭血压监测的大型多中心巴西样本中，确定隐匿性高血压的患病率和临床特征。
这是一项基于 teleMRPA 在线平台的二次数据分析的观察性横断面分析研究，该平台包含来自巴西五个地区的 15 个州的 32 个城市。该数据库包括 2018 年因诊室血压<140/90mmHg 而进行家庭血压监测以诊断（诊断组，n=1819）或治疗（治疗组，n=1885）高血压的 3704 名门诊参与者。
在整个研究人群中，隐匿性高血压的患病率为 18.0%，在诊断组和治疗组中分别为 15.4%和 20.4%。在诊室血压分类为高正常（收缩压[SBP]=130-139mmHg 或舒张压[DBP]=85-89mmHg）的患者中，隐匿性高血压更常见，其次是诊室血压分类为正常（SBP=120-129mmHg 或 DBP=80-84mmHg）和最佳（SBP<120mmHg 和 DBP<80mmHg）的患者，诊断组中分别为 28.3%、13.4%和 4.4%，治疗组中分别为 30.8%、18.8%和 7.1%。
在诊室血压<140/90mmHg 的个体中，隐匿性高血压的患病率显著，在诊室血压高正常的患者中患病率更高，在已经使用降压药物的患者中甚至更高。
